Related Experiment Video
Updated: Jul 23, 2025
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
Multistage Anticoagulant Surfaces: A Synergistic Combination of Protein Resistance, Fibrinolysis, and
Jian Feng1, Jinghong Wang1,2,3, Huanhuan Wang1
1State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, P.R. China.
Abstract:
Anticoagulant surface modification of blood-contacting materials has been shown to be effective in preventing thrombosis and reducing the dose of anticoagulant drugs that patients take. However, commercially available anticoagulant coatings, that is, both bioinert and bioactive coatings, are typically based on a single anticoagulation strategy. This puts the anticoagulation function of the coating at risk of failure during long-term use. Considering the several pathways of the human coagulation system, the synergy of multiple anticoagulation theories may provide separate, targeted effects at different stages of thrombosis. Based on this presumption, in this work, negatively charged poly(sodium p-styrenesulfonate-co-oligo(ethylene glycol) methyl ether methacrylate) and positively charged poly(lysine-co-1-adamantan-1-ylmethyl methacrylate) were synthesized to construct matrix layers on the substrate by electrostatic layer-by-layer self-assembly (LBL). Amino-functionalized β-cyclodextrin (β-CD-PEI) was subsequently immobilized on the surface by host-guest interactions, and heparin was grafted. By adjusting the content of poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA), the interactions between modified surfaces and plasma proteins/cells were regulated. This multistage anticoagulant surface exhibits inertness at the initial stage of implantation, resisting nonspecific protein adsorption (POEGMA). When coagulation reactions occur, heparin exerts its active anticoagulant function in a timely manner, blocking the pathway of thrombosis. If thrombus formation is inevitable, lysine can play a fibrinolytic role in dissolving fibrin clots. Finally, during implantation, endothelial cells continue to adhere and proliferate on the surface, forming an endothelial layer, which meets the blood compatibility requirements. This method provides a new approach to construct a multistage anticoagulant surface for blood-contacting materials.
Insights
This study developed a novel multistage anticoagulant surface for medical devices. It combines inertness, heparin
Area of Science:
- Biomaterials Science
- Surface Chemistry
- Biomedical Engineering
Background:
- Anticoagulant surface modification is crucial for blood-contacting materials to prevent thrombosis.
- Current coatings often rely on single strategies, risking long-term failure.
- Synergistic anticoagulation approaches targeting multiple pathways offer enhanced efficacy.
Purpose of the Study:
- To develop a novel, multistage anticoagulant surface for blood-contacting materials.
- To integrate multiple anticoagulation mechanisms for improved long-term performance.
- To enhance blood compatibility of medical implants.
Main Methods:
- Synthesized charged polymers for electrostatic layer-by-layer self-assembly.
- Immobilized amino-functionalized β-cyclodextrin and grafted heparin.
- Tuned poly(oligo(ethylene glycol) methyl ether methacrylate) content to regulate protein/cell interactions.
Main Results:
- The modified surface demonstrated initial inertness, resisting protein adsorption.
- Heparin provided active anticoagulation, blocking thrombosis pathways.
- Lysine facilitated fibrinolysis, and endothelial cells adhered and proliferated, ensuring biocompatibility.
Conclusions:
- The developed multistage anticoagulant surface offers a promising approach for blood-contacting materials.
- This strategy integrates inertness, anticoagulation, fibrinolysis, and endothelialization.
- It addresses the limitations of single-strategy coatings for improved hemocompatibility.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:29Venous Thrombosis III: Interprofessional Care
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...